Point72 Asset Management's Schedule 13G Filing for Dianthus Therapeutics

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 5.3% of the common stock of Dianthus Therapeutics, Inc. The filing indicates that Point72 Asset Management maintains investment and voting power over the shares held by Point72 Associates, LLC, an investment fund it manages. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. The filing is made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934. The shares reported are based on 39,804,361 shares outstanding as of the completion of Dianthus Therapeutics' underwritten public offering on September 11, 2025. The filing includes a Joint Filing Agreement among the reporting persons.